Uncategorized

Genexine’s Long-acting Anemia Treatment GX-E4 Phase 3 Clinical Trial Interim Result Is Presented at WCN2023, Confirmed Non-inferiority Compared to Mircera

A clinical-staged proprietary platform technology biotech company Genexine and its Asian regional partner, KG Bio unveiled the interim results of phase 3 clinical trial of GX-E4, a candidate for CKD induced anemia.

Genexine’s Long-acting Anemia Treatment GX-E4 Phase 3 Clinical Trial Interim Result Is Presented at WCN2023, Confirmed Non-inferiority Compared to Mircera Read More »

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – April 11, 2023

CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employees’ acceptance of employment with the company.

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – April 11, 2023 Read More »

Scroll to Top